New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
10:12 EDTGLF, BBEP, RDY, YUM, TSO, MTB, FRME, AVGO, ENOC, BGS, RFMD, HBC, DRC, CRL, LLY, VRA, MCHPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Avago (AVGO) upgraded to Buy from Neutral at Goldman... BreitBurn Energy (BBEP) upgraded to Neutral from Underperform at Credit Suisse... Charles River Labs (CRL) upgraded to Outperform from Market Perform at Wells Fargo... Dresser-Rand (DRC) upgraded to Positive from Neutral at Susquehanna... First Merchants (FRME) upgraded to Outperform from Market Perform at Keefe Bruyette... GulfMark Offshore (GLF) upgraded to Outperform from Market Perform at Wells Fargo... HSBC (HBC) upgraded to Buy from Hold at Deutsche Bank... M&T Bank (MTB) upgraded to Outperform from Market Perform at Keefe Bruyette... Microchip (MCHP) upgraded to Neutral from Sell at Goldman... RF Micro Devices (RFMD) upgraded to Overweight from Equal Weight at Barclays... Tesoro (TSO) upgraded to Outperform from Neutral at Credit Suisse... Vera Bradley (VRA) upgraded to Buy from Hold at Jefferies... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Yum! Brands (YUM) upgraded to Buy from Neutral at Goldman... Charles River Labs (CRL) upgraded to Overweight from Neutral at JPMorgan... Eli Lilly (LLY) upgraded to Neutral from Underperform at Cowen... EnerNOC (ENOC) upgraded to Outperform from Market Perform at Raymond James... Dr. Reddy's Labs (RDY) upgraded to Outperform from Neutral at Credit Suisse.
News For AVGO;BBEP;DRC;FRME;GLF;HBC;MTB;MCHP;RFMD;TSO;VRA;BGS;YUM;LLY;ENOC;RDY;CRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
06:37 EDTLLYEli Lilly expands San Diego biotechnology center
Subscribe for More Information
06:33 EDTLLYEli Lilly raises FY15 EPS view to $3.20-$3.30 from $3.10-$3.20, consensus $3.18
Narrows FY15 revenue guidance to $19.7B-$20B from $19.5B-$20B, consensus $19.8B.
06:30 EDTLLYEli Lilly reports Q2 adjusted EPS 90c, consensus 74c
Subscribe for More Information
July 22, 2015
17:06 EDTGLFGulfMark Offshore sees FY15 drydock $15M-$17M
Sees FY15 direct operating expenses $175M-$180M.
17:05 EDTGLFGulfMark Offshore sees Q3 revenue $65M-$70M, consensus $75.44M
Subscribe for More Information
17:03 EDTGLFGulfMark Offshore reports Q2 adjusted EPS (27c), consensus (47c)
Reports Q2 revenue $74.46M, consensus $74.53M. "Our expense reduction initiatives continue to yield better than anticipated savings. We now believe that we will be able to capture about $60M of annual direct operating expense savings, an additional $25M in savings over our previous goal of about $35M," said the company.
16:13 EDTBGSB&G Foods cuts FY15 adjusted EPS to $1.44-$1.50, consensus $1.47
Raises FY15 revenue to $875M-$885M, consensus $869.94M. Raises adjusted EBITDA to $199M-$204M. EPS guidance cut "primarily due to an additional 4.2M shares outstanding following the company’s Q2 public offering."
16:11 EDTBGSB&G Foods reports Q2 adjusted EPS 34c, consensus 34c
Reports Q2 revenue $193.65M, consensus $209.19M.
15:26 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:51 EDTAVGO, MCHPEarnings Watch: Qualcomm reports after speculations of potential breakup
Qualcomm (QCOM) is expected to report third quarter earnings after the close on July 22, with a conference call scheduled for 4:45 pm ET. Qualcomm is a maker of semiconductors and telecommunications equipment. EXPECTATIONS: Analysts are looking for earnings per share of 95c on revenue of $5.85B. EPS consensus ranges 90c-$1.05 on a revenue range of $5.59B-$6.08B, according to First Call. LAST QUARTER: On April 22, Qualcomm reported Q2 EPS of $1.40 against expectations for $1.33, and revenue of $6.89B versus estimates of $6.83B. The company also cut its FY15 EPS guidance to $4.60-$5.00 from $4.85-$5.05 and lowered projected revenue to $25B-$27B from $26.3B-$28B, saying it expects pressure in its semiconductor business due to customer shifts in the premium segment and a decline in Qualcomm's share at an unnamed large customer. NEWS: On May 8, Reuters reported that EU antitrust regulators asked Qualcomm's competitors how the company's licensing and business practices affect them, and on July 16, the European Commission confirmed two formal antitrust investigations of the company. On May 25, Qualcomm and Daimler (DDAIF) announced a strategic collaboration to develop connected car technology. Coming on the heels of Avago's (AVGO) May 28 agreement to acquire Broadcom (BRCM), Bloomberg quoted a source later that day as saying Qualcomm, Intel (INTC), Altera (ALTR), Analog Devices (ADI), Maxim Integrated (MXIM), Texas Instruments (TXN), and Microchip Technology (MCHP) are all considering their own M&A opportunities. Note that on June 1, Intel announced an agreement to acquire Altera. On June 23, Semiconductor Manufacturing International (SMI), Qualcomm, Huawei, and Imec announced the formation of a joint venture to focus on a type of 14 nanometer technology. More recently, the Wall Street Journal reported on July 20 that Qualcomm is "expected" to begin a comprehensive strategic review which may include the possibility of a breakup following pressure from "activist" shareholder Jana Partners, according to sources, adding that the move could be announced concurrent with Wednesday's earnings release. STREET RESEARCH: Following last quarter's earnings report, Exane BNP Paribas downgraded Qualcomm to Neutral from Outperform, while both Canaccord and Brean Capital lowered price targets for the stock after "disappointing" guidance. Meanwhile, Citi said it expects the company's chip business to recover in 2016 despite this "very bad year." On May 28, CLSA said it sees continued pressure on Qualcomm chipsets, potentially spurring the company to consider making an acquisition, and on June 2, Craig-Hallum noted that Skyworks (SWKS) would be a great fit for Qualcomm. On June 24, Summit Research called Applied Micro Circuits (AMCC) an "affordable" target for Qualcomm, with AMD (AMD) and Cavium (CAVM) also looking like potential takeover candidates. On June 29, Drexel Hamilton downgraded Qualcomm to Sell from Hold, citing expected price cuts. Lastly, following media reports on July 20 that Qualcomm could be weighing a breakup, Bernstein said that such a "dis-synergistic" split would likely destroy value rather than create it. PRICE ACTION: Shares of Qualcomm are down more than 1% to $64.37 in afternoon trading ahead of Wednesday's earnings report.
12:35 EDTMCHPAnalog chip makers fall after Linear cites weak end market demand
Subscribe for More Information
10:59 EDTLLYBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:05 EDTLLYEli Lilly gaps down, retraces, levels to watch
Subscribe for More Information
08:40 EDTLLYEli Lilly July weekly volatility elevated into Q2 and Alzheimer's drug data
Subscribe for More Information
07:18 EDTLLYEli Lilly drops 3% to $83 after reporting Alzheimer's drug data
Subscribe for More Information
07:06 EDTLLYEli Lilly's solanezumab for Alzheimer's supports 'delayed-start' use
Subscribe for More Information
July 21, 2015
19:00 EDTAVGOOn The Fly: After Hours Movers
Subscribe for More Information
10:24 EDTYUMOptions with decreasing implied volatility
Subscribe for More Information
July 20, 2015
10:13 EDTYUMOptions with decreasing implied volatility
Subscribe for More Information
07:32 EDTLLYAlzheimer's Association to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use